Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Drug Discovery Today

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2009.11.006PMID 19961955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer.

  2016cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009influential reference
• The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.

  2009cited by this paper
• Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

  2009cited by this paper
• Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

  2009cited by this paper
• Pharmacogenetics and pharmacogenomics of anticancer agents

  2009cited by this paper
• A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

  2009cited by this paper
• LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance

  2009cited by this paper
• Linking somatic genetic alterations in cancer to therapeutics.

  2009cited by this paper
• Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

  2009influential reference
• Principles of cancer therapy: oncogene and non-oncogene addiction.

  2009cited by this paper
• Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

  2009cited by this paper
• Do molecularly targeted agents in oncology have reduced attrition rates?

  2009cited by this paper
• KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.

  2009influential reference
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs

  2009cited by this paper
• Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer

  2009cited by this paper
• PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial.

  2009cited by this paper
• Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

  2009influential reference
• Structure-based design of molecular cancer therapeutics.

  2009cited by this paper
• Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

  2009cited by this paper
• Comparative Genomic Hybridisation Arrays: High-Throughput Tools to Determine Targeted Therapy in Breast Cancer

  2008cited by this paper
• BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells

  2008cited by this paper
• MicroRNA signatures as diagnostic and therapeutic targets.

  2008cited by this paper
• Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

  2008cited by this paper
• The State of Innovation in Drug Development

  2008cited by this paper
• Targeting CYP17: established and novel approaches in prostate cancer.

  2008cited by this paper
• KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

  2008cited by this paper
• KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

  2008cited by this paper
• DNA sequencing of a cytogenetically normal acute myeloid leukemia genome

  2008cited by this paper
• Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays

  2008cited by this paper
• Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases

  2008cited by this paper
• DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.

  2008cited by this paper
• Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

  2008cited by this paper
• Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

  2008influential reference
• Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine.

  2008cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Pharmacogenetics in Breast Cancer Therapy

  2008cited by this paper
• Oncogene addiction.

  2008cited by this paper
• Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

  2008influential reference
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

  2008cited by this paper
• Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development.

  2007cited by this paper
• Trends in the Use and Role of Biomarkers in Phase I Oncology Trials

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

  2007cited by this paper
• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

  2007cited by this paper
• Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

  2007cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• Dose-finding in phase I clinical trials based on toxicity probability intervals

  2007influential reference
• High-throughput oncogene mutation profiling in human cancer

  2007cited by this paper
• Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

  2007cited by this paper
• Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction?

  2007cited by this paper
• Economics of new oncology drug development.

  2007cited by this paper
• Cancer biomarkers: current issues and future directions.

  2007cited by this paper
• Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Pharmacodynamic biomarkers for molecular cancer therapeutics.

  2007cited by this paper
• AACR–FDA–NCI cancer biomarkers collaborative

  2007cited by this paper
• Biomarker qualification pilot process at the US Food and Drug Administration

  2007cited by this paper
• Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole.

  2007cited by this paper
• Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

  2007cited by this paper
• The Role of SN‐38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity

  2007cited by this paper
• TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

  2006cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• Molecular imaging in the development of cancer therapeutics.

  2006cited by this paper
• Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.

  2006cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• New approaches to molecular cancer therapeutics

  2006cited by this paper
• Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

  2006cited by this paper
• Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

  2006cited by this paper
• Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer

  2006cited by this paper
• Using biomarkers in drug development.

  2006cited by this paper
• Use of flow-through peptide-microarrays for cell-lysate profiling

  2006influential reference
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• B-RAF is a therapeutic target in melanoma

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma.

  2004cited by this paper
• Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

  2004cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

  2004cited by this paper
• Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

  2004cited by this paper
• The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones

  2003influential reference
• How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development.

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

  2003cited by this paper
• Pharmacogenomics--drug disposition, drug targets, and side effects.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper

• Overview of drugs approved by the FDA in 2022

  2023cites this paper
• Noncoding RNome as Enabling Biomarkers for Precision Health

  2022cites this paper
• Analytical Validation of Quantitative Pharmacodynamic Methods used in Clinical Cancer Studies

  2021cites this paper
• Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development

  2021cites this paper
• Methoden klinischer Prüfung in der Onkologie

  2021cites this paper
• Pharmacodynamic biomarker for Hepatocellular carcinoma C: Model-based evaluation for pharmacokinetic–pharmacodynamic responses of drug

  2021cites this paper
• Phosphoproteome analysis reveals dynamic heat shock protein 27 phosphorylation in tanshinone IIA-induced cell death.

  2020cites this paper
• Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer.

  2020cites this paper
• Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients.

  2019cites this paper
• Exosomes for Non‐Invasive Cancer Monitoring

  2018cites this paper
• Deformability-based separation and single-cell sequencing of circulating tumor cells in prostate cancer

  2018cites this paper
• Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.

  2017cites this paper
• Preclinical and Early Clinical Development of Chemotherapeutic Drugs, Mechanism‐Based Agents and Biologics

  2017cites this paper
• Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges

  2017cites this paper
• Directing Circulating Tumor Cell Technologies Into Clinical Practice

  2016cites this paper
• Why and how have drug discovery strategies in pharma changed? What are the new mindsets?

  2016cites this paper
• Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?

  2016cites this paper
• Unveiling changes in the landscape of patient populations in cancer early drug development

  2016cites this paper
• Discover, Develop & Validate--Advance and Prospect of Tumor Biomarkers.

  2015cites this paper
• Circulating Tumor Cells: A Window to Understand Cancer Metastasis, Monitor and Fight Against Cancers

  2015cites this paper
• Biomarkers for pancreatic cancer : identification, validation and clinical application

  2015cites this paper
• Integrating transcriptomics and proteomics to show that tanshinone IIA suppresses cell growth by blocking glucose metabolism in gastric cancer cells

  2015cites this paper
• Identification of Circulating MicroRNAs as Biomarkers in Glioblastoma

  2015cites this paper
• MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges

  2015cites this paper
• The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

  2015cites this paper
• A framework for prescription in exercise-oncology research†

  2015cites this paper
• The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

  2015cites this paper
• Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

  2015cites this paper
• Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?

  2015cites this paper
• Modeling and simulation analysis of the relationship between lesion recurrence on brain images and clinical recurrence in patients with ischemic stroke

  2015cites this paper
• Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer

  2015cites this paper
• Biotechnology in Drug Discovery and Development for Cancer

  2014cites this paper
• Metabolic factors determining outcome in chemotherapy : studies with pazopanib

  2014cites this paper
• Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  2014cites this paper
• Circulating MicroRNA Biomarkers for Glioma and Predicting Response to Therapy

  2014cites this paper
• Fluorescence-based co-culture of normal and cancerous cells as an indicator of therapeutic effects in cancer.

  2014cites this paper
• Proteomic Biomarker Discovery: Review of the Science and Its Challenges with Clinical Samples.

  2014cites this paper
• γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

  2014cites this paper
• Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

  2014cites this paper
• Drug development failures in oncology often originate from a lack of understanding regarding the biology of the drug

  2013cites this paper
• Biomarker-driven patient selection for early clinical trials

  2013cites this paper
• Biomarqueurs cellulaires circulants dans les cancers avancés

  2013cites this paper
• Modifying phase I methodology to facilitate enrolment of molecularly selected patients.

  2013cites this paper
• Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

  2013cites this paper
• Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.

  2013cites this paper
• Targeting PI3K in Cancer: Any Good News?

  2013cites this paper
• Cytokeratin 18 (CK18) and Caspase-Cleaved CK18 (ccCK18) as Response Markers in Anticancer Therapy

  2012cites this paper
• Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

  2012cites this paper
• Improving the outcomes: developing cancer therapeutics.

  2012cites this paper
• Target Significance and Probe Validation *

  2012cites this paper
• Predictive in vivo animal models and translation to clinical trials.

  2012cites this paper
• Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

  2012cites this paper
• Targeted molecular imaging: target significance and probe validation.

  2012cites this paper
• Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use

  2012cites this paper
• Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.

  2012cites this paper
• Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies.

  2012cites this paper
• Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.

  2012cites this paper
• Cytokeratins - Tools in Oncology

  2012cites this paper
• Opportunities and challenges in oncology targeted drug development : an assessment of the use of prevalence and companion diagnostic performance thresholds to guide clinical trial strategies

  2012cites this paper
• Targeted Molecular Imaging

  2012cites this paper
• Design, synthesis, and evaluation of small molecule Hsp90 probes.

  2011cites this paper
• Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress

  2011cites this paper
• Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines

  2011cites this paper
• Nanomedicine(s) under the microscope.

  2011cites this paper
• Poly(ADP‐Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

  2011cites this paper
• Discontinued drugs in 2010: oncology drugs

  2011cites this paper
• Identification of Tumor Suppressors and Oncogenes from Genomic and Epigenetic Features in Ovarian Cancer

  2011cites this paper
• Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box

  2011cites this paper
• Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives

  2011cites this paper
• Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

  2010cites this paper
• Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

  2010cites this paper
• Molecular Biomarker Analyses Using Circulating Tumor Cells

  2010cites this paper
• Targeting the HGF/c-Met Axis: State of Play

  2010cites this paper
• Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors?

  2010cites this paper
• Biomarkers of Cancer

  2010cites this paper
• Fit-for-purpose biomarker method validation in anticancer drug development.

  2010cites this paper
• The review presents strategies for fit-for-purpose method validation of biomarker assays to help ensure generation of robust data during clinical trials and to satisfy regulatory requirements. Fit-for-purpose biomarker method validation inanticancerdrugdevelopment

  2010cites this paper
• Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

  2010cites this paper
• Translating cancer research into targeted therapeutics

  2010cites this paper
• Patient benefits from psychosocial care: screening for distress and models of care.

  2010cites this paper
• A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit

  2010cites this paper